Baricitinib
| CAS No. | 1187594-09-7 |
|---|---|
| MDL No. | MFCD21608464 |
| MF | C16H17N7O2S |
| MW | 371.40 |
| InChI Key | XUZMWHLSFXCVMG-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Baricitinib is a pyrrolopyrimidine with a 1-[3-(cyanomethyl)-1-(ethanesulfonyl)azetidin-3-yl]-1H-pyrazol-4-yl group at position 5. It is an FDA-approved selective JAK1/JAK2 inhibitor used for rheumatoid arthritis. It functions as an antirheumatic, anti-inflammatory, immunosuppressive, antiviral, and EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It belongs to pyrrolopyrimidines, pyrazoles, azetidines, sulfonamides, and nitriles.
| CAS No. | 1187594-09-7 |
|---|---|
| Product Name | Baricitinib |
Biological Targets
JAK1·JAK2
Associated Conditions
Sjogren syndrome·neuromyelitis optica·myositis·severe acute respiratory syndrome·brain injury·
* The information provided here is compiled from public sources and is for reference only.
